Taipei, Taiwan, June 10, 2025 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for May 2025 reached NT$1,129 million. This represents a 27% decrease year-over-year (YoY). Lotus's May year-to-date (YTD) revenue stood at NT$8,433 million, representing an 8% YoY growth.
Lotus's Asia business saw a 4% YoY revenue increase in May, mainly attributable to the sustained robust growth in Southeast Asia, in particular following the successful integration of Teva operations in Thailand. Korea saw one-off lower revenue due to the extended May holiday, which shifted some revenues earlier into April. Adjusting for the seasonality, Korea maintained its momentum and saw a 7% YoY growth in combined revenue for April and May months. Export markets experienced an 63% YoY decline, mainly due to the seasonal nature of lenalidomide revenue recognition.
During the month, Lotus has continued to forge important strategic partnerships globally and strengthened its product portfolio. On 8 May, an exclusive agreement with Supernus was signed for Lotus to bring Qelbree, an extended-release formulation of viloxazine, a novel nonstimulant medication for the treatment of ADHD to major APAC markets. On 8 May, Lotus received the exclusive development, manufacturing, registration and commercialisation rights to bring LENZ’s LNZ100 in the Republic of Korea and certain countries in Southeast Asia. LNZ100 is the first and only aceclidine-based eye drop to improve near vision in people with presbyopia.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness
Media Inquiries:
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com